MiR-29b Expression Is Associated With Disease-Free Survival in Patients With Ovarian Serous Carcinoma. Issue 4 (1st April 2009)

• Record Type: Journal Article
• Authors: Flavin, Richard; Smyth, Paul; Barrett, Ciara; Russell, S.; Wen, Hannah; Wei, Jianjun; Laios, Alex; O'Toole, Sharon; Ring, M.; Denning, K.; Li, J.; Aherne, S.; Sammarae, D.; Aziz, N. A.; Alhadi, A.; Finn, Sephen P.; Loda, M.; B, Sheppard; Sheils, Orla; O'Leary, John J.
• Is Part Of: International journal of gynecological cancer. Volume 19:Issue 4(2009)
• Page Start: 641-647
• Page End: 641-647
• Publication Date: 2009-04-01
• Subjects: Micro-RNA -- Ovarian serous carcinoma -- Biomarkers; Generative organs, Female -- Cancer -- Periodicals; 616.99465
• DOI: 10.1111/IGC.0b013e3181a48cf9
• Languages: English
• ISSNs: 1048-891X

Abstract

Abstract : Micro-RNAs are a group of small noncoding RNAs approximately 22 nucleotides in length. Recent work has shown differential expression of mature micro-RNAs in human cancers. We characterized the alteration in expression of miR-29b in ovarian serous carcinoma. miR-29b expression was analyzed using quantitative stem-loop reverse transcriptase polymerase chain reaction on a set of 50 formalin-fixed, paraffin-embedded ovarian serous carcinoma samples. Protein expression of p53, estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, Ki-67, and insulinlike growth factor 1 was quantified in the corresponding tissue microarray. The expression profile of miR-29b was correlated with clinicopathological and patient survival data. We provide definitive evidence that miR-29b is down-regulated in a significant proportion of ovarian serous carcinomas and is associated with specific clinicopathological features, most notably high miR-29b expression being associated with reduced disease-free survival.